What are the opening hours?

Monday 09:00 - 18:00 Tuesday 09:00 - 18:00 Wednesday 09:00 - 18:00 Thursday 09:00 - 18:00 Friday 09:00 - 18:00

VCorp Capital, BO1-A, Level 16, Menara 2, No. 3, KL Eco City, Kuala Lumpur (2026)

10/06/2026

ZUS Coffee got lucky. At least three times.

Most brands handed the same luck would have blown it.

That's exactly why we're starting here.

Today we're launching — 100 growth stories of Malaysian companies that turned a moment into a movement. We'll break down what actually drove the growth, beyond the headlines.

First up: how a 200 sq ft kiosk became a billion-ringgit, 1,000+ store regional brand — and the systems hiding underneath the "luck."

99 more to come. Follow VCorp Capital for a new Made-in-Malaysia growth story every week.

Which Malaysian company should we feature next? Drop a name in the comments.

05/06/2026

Before you fill in that IPO application form — read this.

Big Caring Group's upcoming Bursa Main Market listing is shaping up to be one of Malaysia's headline capital markets events this year. The brand is everywhere. The growth story is real. But the best investment outcomes come from asking sharper questions, not simply reading the marketing narrative.

So here's both sides of the trade, as honestly as we can lay it out.

🟢 The Bull Case

Market leadership in a resilient category. 626 outlets, five brands, Malaysia's largest pharmacy chain by a significant margin. Pharmacy retail doesn't disappear in a downturn — if anything, heightened health awareness since the pandemic has accelerated category growth. BCG is the largest beneficiary of consolidation in an industry where independent pharmacies are steadily losing share to organised chains.

Real operational investment, not just narrative. For FY2025, BCG posted a net profit of RM143 million on revenue of RM3.41 billion, with same-store sales growth of 9.6%, up from 7.3% in FY2024. These aren't fabricated numbers — they're backed by SAP on AWS infrastructure, AI-driven replenishment, 160+ robots in a new automated distribution centre, and a consolidated headquarters. Tangible capital deployed for tangible operational outcomes. The Exchange Asia

A genuinely diversified model. Retail pharmacy, own-brand manufacturing, B2B distribution to hospitals and clinics, allied health via Your Physio, and early-stage telehealth. This isn't a one-trick pharmacy story anymore.

Structural tailwinds are real. Malaysia's ageing population, growing middle class, and rising healthcare expenditure form a strong multi-decade backdrop. BCG is positioned to capture all of it.

🔴 The Bear Case

This IPO is partly a debt-reduction event. As of January 31, 2026, BCG's borrowings stood at RM1.3 billion, with an average interest cost of 5.2% per annum. A core stated use of IPO proceeds is repayment of bank borrowings from the CARiNG and Medispec acquisitions. That's not inherently problematic — it's a standard PE recapitalisation strategy. But retail investors should understand clearly that a meaningful portion of what they're funding is cleaning up the balance sheet, not incremental growth investment. The Exchange Asia

The offer-for-sale component is substantial. Of the shares being offered, up to 17.5% of the enlarged share base comes from selling shareholders. Creador is paring its stake from 33.7% to 19.4%, while the founders are offering a 5.1% stake. Again — not unusual for a PE-backed IPO. But it's important context. You're partly providing liquidity to existing shareholders, not just funding a growth story. The Edge Malaysia

The platform narrative needs to be proven. The RM20 billion valuation implies premium multiples. The infrastructure is genuinely being built. But compounding network effects, digital engagement metrics, and services revenue contribution are not yet publicly quantified. Until the full prospectus arrives with segment-level financials, investors are taking some things on trust.

Integration complexity is real. Five brands, hundreds of outlets, multiple acquired businesses, a new distribution centre, and a large-scale ERP migration — all simultaneously. Ex*****on risk in any one dimension could affect near-term financial performance.

The framework, depending on your profile:

For institutional investors with a 3–5 year horizon: worth serious consideration if you have conviction in the platform evolution. The central diligence question is whether entry price adequately reflects ex*****on risk at the current transformation stage.

For retail investors: wait for the full prospectus. Four numbers will tell you most of what you need to know — net profit and EBITDA margins by segment, debt-to-equity ratio post-IPO, same-store sales growth trend, and the breakdown between proceeds going to the company versus selling shareholders.

The bottom line: BCG is a real business with real scale and a credible path to becoming Malaysia's leading healthcare platform. The IPO structure is designed to serve multiple objectives simultaneously — and that's fine. That's how private equity works. Your job as an investor is simply to figure out exactly what you're paying for, and whether the residual growth story justifies the price once all those other objectives are served.

What questions would you want answered before making a decision on this one? Drop them in the comments — once the full prospectus is out, we'll be publishing a deeper dive into the numbers.

Disclaimer: This post represents the views and analysis of our firm based on publicly available information. It is intended for informational purposes only and does not constitute financial, investment, or legal advice. Nothing here should be relied upon when making investment decisions. Readers are encouraged to conduct their own due diligence and consult a qualified financial adviser before acting on any information presented.

29/05/2026

Before the roadshow begins and the valuation gets debated, there's a more fundamental question worth settling: is Big Caring Group a pharmacy chain, or is it becoming a healthcare platform?

The distinction is worth billions. Chains trade at retail multiples. Platforms trade at ecosystem multiples. The gap between those two valuation frameworks can be enormous.

Here's the evidence.

What a chain does: More stores, more revenue. Value creation is linear.

What a platform does: It creates an ecosystem where customers, partners, service providers, and suppliers interact in ways that compound. As the network grows, each participant becomes more valuable because of every other participant. Value creation becomes non-linear.

BCG is building the structural components of a platform. Here's the architecture, as we read it.

Multi-brand, unified infrastructure. BIG. CARiNG. Georgetown. Wellings. Ting. Five brands, one holding group, one technology backbone. The multi-brand strategy isn't just about market coverage — it's about owning different customer segments and geographic markets under a single operational and data layer. That's a platform play dressed in retail clothing.

A 5,000-touchpoint partner ecosystem. BCG references over 5,000 healthcare partner touchpoints across hospitals, clinics, physiotherapy centres, and other providers. When you have that many partner relationships — each generating referrals, prescriptions, and wellness demand — you have the beginnings of a two-sided network. Patients on one side. Healthcare providers on the other. BCG as the connective tissue. That's a platform structure, and it compounds.

Upstream control. Platform businesses don't just sit between buyers and sellers. They control key infrastructure layers. BCG's ownership of manufacturing, importing, and wholesale distribution gives it control over the supply layer of its own ecosystem. This opens a B2B marketplace model where BCG's distribution infrastructure could eventually serve as the fulfilment layer for independent clinics and smaller pharmacy chains — not just BCG's own stores. That's a significant total addressable market expansion.

Services as the expansion vector. Platform businesses grow through services, not just products. Your Physio is the most visible move here. Add tele-consultation, and BCG starts to resemble a hybrid model — physical network plus services plus digital health plus product distribution. The SAP on AWS cloud layer is what makes this coherent: a single data backbone across all touchpoints means BCG can track a patient's full healthcare journey — pharmacy visits, physio sessions, tele-consults, product purchases — and use that to deliver more personalised, proactive care.

What still needs to be proven: True platform businesses require network effects and measurable digital engagement. The structural intent at BCG is clear. But until the full prospectus is available, the questions worth asking are: Is growth in the ecosystem still primarily linear, or are genuine network effects emerging? Is BCG actively opening its platform to external participants — insurers, diagnostics providers, health apps? What does the active digital member base actually look like, and how does it drive cross-sell?

The answers to those three questions will tell you whether the RM20 billion valuation is a forward-looking bet on platform evolution, or a stretch multiple on a sophisticated retail business.

How are you approaching the valuation framework for this one — pharmacy retail peers, or something broader?

Disclaimer: This post represents the views and analysis of our firm based on publicly available information. It is intended for informational purposes only and does not constitute financial, investment, or legal advice. Nothing here should be relied upon when making investment decisions. Readers are encouraged to conduct their own due diligence and consult a qualified financial adviser before acting on any information presented.

28/05/2026

Growth is easy to claim. Scalable growth is genuinely hard to build.

As Big Caring Group heads toward its Bursa Main Market listing, the question that actually matters for long-term investors isn't how many stores they have today. It's whether the operating model can handle 200 more stores without breaking.

Based on what's been disclosed so far — the answer appears to be yes.

Here's why that question matters. Pharmacy chains face a specific scaling paradox. Every new outlet requires physical logistics: inventory stocking, replenishment, cold-chain management, staff training, regulatory compliance. The more stores you add, the more complex your supply chain. If infrastructure doesn't scale ahead of store count, you get margin squeeze and degrading customer experience. BCG currently operates 626 outlets and has guided for 40 to 50 new openings per year over the next three to five years — a potential 35–40% expansion.

For that kind of ambition to work, your distribution infrastructure has to lead your store count. Not lag it.

The Klang distribution centre is where this becomes concrete.

The new facility went live with: more than 160 robots, 700 high-density storage racks, and over 90,000 order lines processed daily. AI-driven smart replenishment anticipates demand by location. The system has improved picking efficiency by 76.5% and achieved picking accuracy of 99.8%. It's directly integrated with BCG's cloud-based SAP on AWS platform for real-time data flow across all stores.

What this creates is an operating engine that can handle significantly higher volumes without a linear increase in headcount or complexity. As throughput scales, per-outlet logistics costs should come down. That's genuine operating leverage — and the kind that shows up in EBITDA margins over time.

The detail most people overlook: the new headquarters.

BCG has also consolidated its corporate headquarters in Klang alongside the distribution centre. On the surface this looks like a secondary detail. In practice, it's one of the more important scalability moves they've made.

When multiple acquired brands keep operating with siloed management teams, separate cultures, and independent decision chains, the holding company becomes a coordination tax rather than a value-add. Centralising headquarters is a deliberate signal that BCG is trying to unify decision-making and ensure capital flows efficiently across the group — not just between five semi-independent pharmacy businesses.

Running through a quick scalability checklist against what's been disclosed publicly:

✅ Centralised data and inventory control — SAP on AWS, unified platform
✅ Automation at logistics bottlenecks — 160+ robots, AI replenishment, new Klang DC
✅ Capacity runway that leads, not lags, store count — DC built ahead of constraint
✅ Organisational infrastructure matching physical expansion — HQ centralisation
⬜ Standardised store playbooks across five brand formats — harder to assess from public documents; worth probing in the full prospectus

Four of five confirmed. The fifth — whether BCG has a genuinely standardised rollout playbook across five distinct brand formats — is the question we'd be asking management directly.

Scalability isn't a narrative. It's an engineering problem. BCG appears to have approached it as one.

For those who've scaled physical retail: what's the one infrastructure investment you wish you'd made earlier? We consistently hear the same answer — distribution. The constraint you don't notice until it's strangling you.

Disclaimer: This post represents the views and analysis of our firm based on publicly available information. It is intended for informational purposes only and does not constitute financial, investment, or legal advice. Nothing here should be relied upon when making investment decisions. Readers are encouraged to conduct their own due diligence and consult a qualified financial adviser before acting on any information presented.

22/05/2026

A pharmacy chain trades at pharmacy multiples.

A healthcare platform trades at something much higher.

Big Caring Group is trying to become the latter — and they have spent years building the revenue stack to prove it.

Here is how it layers:

→ Layer 1: 626 pharmacy outlets. High frequency. Recession-resilient. The anchor.
→ Layer 2: Own-brand nutraceuticals. 2-4x the gross margin of third-party products.
→ Layer 3: B2B distribution to 5,000+ hospital and clinic touchpoints. Sticky. Recurring. Invisible to consumers.
→ Layer 4: Your Physio (57.1% stake, RM32.8m investment). Allied health services. High margin. Cross-sell goldmine.
→ Layer 5: Telehealth. Early stage but real optionality.

The pharmacy is the door. Not the destination.

20/05/2026

There's a principle in capital markets that's worth remembering: the best time to list is when your business has multiple stories to tell.

Single-format businesses trade at single-format multiples. But when a company can demonstrate complementary revenue streams at different points on the margin spectrum, it earns the right to be compared against a broader — and usually more richly valued — peer set.

Big Caring Group has spent several years building exactly this kind of architecture. Here's how the layers stack up.

Layer 1 — Retail Pharmacy

626 outlets across BIG, CARiNG, Georgetown, Wellings, and Ting. This is the anchor: high-frequency, recession-resilient, and underpinned by Malaysia's ageing population and rising health awareness. But retail pharmacy on its own is a thin-margin, highly competitive game. BCG understood that early, and built accordingly.

Layer 2 — Own-Brand and Nutraceutical Products

Through the CARiNG acquisition and organic development, BCG now manufactures, imports, markets, and distributes its own healthcare and nutraceutical products. This is the classic retail playbook applied to healthcare. Build the distribution network first, then use it to push higher-margin proprietary products. A BCG own-brand product typically carries two to four times the gross margin of a third-party equivalent.

Layer 3 — B2B Distribution and Wholesale

BCG's distribution capabilities extend well beyond its own stores, reaching more than 5,000 hospitals, clinics, and healthcare partner touchpoints across Malaysia. The Medispec acquisition deepened this upstream capability significantly. This channel is largely invisible to consumers but highly valuable to investors: sticky, recurring, and leveraging the same infrastructure that serves the retail network.

Layer 4 — Allied Health Services

This is where the BCG story becomes genuinely interesting. BCG took a 57.1% controlling stake in Your Physio for RM32.8 million — giving it a meaningful foothold in physiotherapy, rehabilitation, and preventive care, which are among the fastest-growing segments in Malaysian healthcare.

Strategically, this extends BCG's relationship with a customer beyond a transactional pharmacy visit into an ongoing healthcare journey. Someone comes in for physio, picks up supplements, fills a prescription. The cross-sell potential is considerable, and services revenue carries a margin profile that looks very different from product retail.

Layer 5 — Telehealth and Digital Health

BCG has also signalled investment in tele-consultation services. This remains early-stage relative to the core business, but it's a meaningful optionality play. As Malaysians become more comfortable with hybrid care models, BCG has the brand trust, physical network, and digital infrastructure to become a serious player in integrating online consultation with offline fulfilment.

The investor lens: Don't look only at top-line pharmacy revenue when the full prospectus drops. Ask specifically for the revenue and margin breakdown by segment. The richer the mix — particularly the contribution from own-brand products and services — the more defensible and scalable the earnings quality.

BCG is building towards a model where the pharmacy outlet is the door, not the destination. That's a fundamentally different — and more valuable — business than a chain that sells medicine.

Which of BCG's revenue streams do you think has the most untapped potential over the next five years? We'd argue the allied health layer, but we're curious where others see the bigger opportunity.

Disclaimer: This post represents the views and analysis of our firm based on publicly available information. It is intended for informational purposes only and does not constitute financial, investment, or legal advice. Nothing here should be relied upon when making investment decisions. Readers are encouraged to conduct their own due diligence and consult a qualified financial adviser before acting on any information presented.

19/05/2026

Last week, we opened our doors to the cameras and the result was something we're genuinely proud of. A big thank you to Infinite Loop Media for their professionalism and vision in bringing our story to the screen. Stay tuned for the final cut! 🎬

14/05/2026

Most people look at Big Caring Group's IPO and see a pharmacy chain going public.

We see a data infrastructure story.

That distinction is worth billions in valuation.

Here is what is happening beneath the surface before BCG hits Bursa:

→ They inherited 5 different tech stacks after acquiring CARiNG. They fixed it with SAP on AWS — enterprise-grade, cloud-based, unified across 626 outlets.
→ Their new Klang distribution centre runs 160+ robots processing 90,000 order lines per day with AI-driven replenishment.
→ The result: lower stockouts, better working capital, faster decisions. Operating leverage that shows up in EBITDA.

Digitisation done right is not a cost line. It is a multiple expansion lever.

The infrastructure is there. The question is how fast it flows through to the financials.

12/05/2026

Most people look at Big Caring Group's IPO and see a pharmacy chain going public.

We see something more interesting than that.

626 outlets. Five brands. Malaysia's largest pharmacy network. Those are the headlines, and they matter. But the story that actually justifies a premium valuation is happening below the surface, in the infrastructure that most investors won't look at closely enough.

Here's the thing about the CARiNG acquisition in 2023: BCG didn't just buy a store network from 7-Eleven Malaysia. They inherited an entirely different technology stack, different inventory systems, and a different customer data architecture. Multiply that across BIG, CARiNG, Georgetown, Wellings, and Ting, and what you have is a holding company that operated more like a loose federation of pharmacies than a unified platform.

That's the classic post-merger integration trap. And how a company handles it tells you almost everything about the quality of management.

BCG's answer was to go enterprise-grade. They adopted RISE with SAP on AWS, a cloud-based ERP and data platform to consolidate operations across their entire network into one system. This is not a small decision. It's the kind of infrastructure commitment you make when you're building for the next decade, not the next quarter.

And critically, they did it before the IPO. That sequencing matters more than most people realize.

Then there's the new Klang distribution centre, and this one deserves attention.

More than 160 robots. 700 high-density storage racks. Over 90,000 order lines processed daily. Since implementation, picking efficiency has improved by 76.5%, with picking accuracy hitting 99.8%. That's not a marketing stat, that's the kind of operational metric that shows up in margins and working capital cycles.

The facility also runs AI-driven smart replenishment that analyses real-time sales patterns by location to anticipate demand before it peaks. Tote-to-person systems for slower-moving items. Shelf-to-person for fast movers. And its location near Port Klang strengthens inbound supply chain efficiency for nationwide distribution.

Why does all this matter for investors?

Because the real value driver in pharmacy retail over the next decade isn't store count. It's who controls the data, and who can act on it. More stores generate richer data. Richer data improves replenishment, targeting, and customer experience. Better experience makes the network harder to dislodge. That's a compounding flywheel, and flywheels are what justify platform multiples rather than retail multiples.

BCG invested in this infrastructure before going public. That's either very good capital discipline or very good storytelling. The prospectus will tell us which specifically, watch for how these investments flow through to inventory turnover, operating margins, and working capital efficiency.

Do you think the market is pricing in BCG's digital transformation, or is it still being valued primarily as a traditional pharmacy roll-up?

Disclaimer: This post represents the views and analysis of our firm based on publicly available information. It is intended for informational purposes only and does not constitute financial, investment, or legal advice. Nothing here should be relied upon when making investment decisions. Readers are encouraged to conduct their own due diligence and consult a qualified financial adviser before acting on any information presented.

07/05/2026

The PE roll-up playbook has four phases.

Most firms nail the first two. The best ones nail all four.

We broke down Big Caring Group's journey from a single Damansara pharmacy to a RM20 billion IPO into a framework every PE investor and founder should know.

Swipe through.

VCorp Capital

10/06/2026

05/06/2026

29/05/2026

28/05/2026

22/05/2026

20/05/2026

19/05/2026

14/05/2026

12/05/2026

07/05/2026

Address

Opening Hours

Telephone

Website

Alerts

Shortcuts

Share

Category

Monday	09:00 - 18:00
Tuesday	09:00 - 18:00
Wednesday	09:00 - 18:00
Thursday	09:00 - 18:00
Friday	09:00 - 18:00